Novo Nordisk is an excellent stock to accumulate gradually after falling more than 70% from its peak, with 2026 looking like a near-term bottom. At about $40.50 it trades at 11-12 times forward earnings, below peers, and analyst targets of $57-65 imply 40-60% upside. Indirect April data show 25mg oral Wegovy beating rivals on weight loss with milder side effects. An OpenAI drug-discovery alliance, a DKK 15 billion buyback, a 4.45% dividend yield and gross margins above 82% add support. x.com 

Novo Nordisk's Wegovy pill is pharma's holy grail and is expanding the obesity market. Its first quarter after launch was stellar, with about 1 million new patients in three months per @TTRAmyloid. Per Novo's CEO, about 35% of pill users are men versus roughly 25% on injections, and 80% of pill starters never tried a GLP-1 before. The 30-minute fasting rule is no real obstacle, especially as the pill sharply cuts hunger, and data so far show better efficacy beats convenience. x.com  x.com  x.com  … Show more

Eli Lilly has the market momentum over Novo Nordisk in GLP-1 drugs. Lilly's Zepbound sold $4B in Q1 against $2.7B for Novo's Wegovy, and Novo's lawsuit over GLP-1 advertising looks defensive. Lilly's direct-to-consumer head start and manufacturing scale appear durable. A GLP-1 market heading to $100B by 2030 remains the most structurally attractive healthcare trade. x.com 

Novo Nordisk is one of the best opportunities in the market and a safe haven in an AI-driven market, crushed while its long-term growth story is rebuilt. It trades at 9x earnings with a 4.64% dividend yield, controls about 80% of the GLP-1 weight-loss pill market and plans to scale oral GLP-1 capacity 10x by 2030. Revenue growth is expected to return to double digits in 2027, and it has partnered with Anthropic on drug discovery. It would need a 110% rally to regain its 200-week average. x.com 

GLP-1 adoption is still early, leaving room for Novo Nordisk and Eli Lilly to remain leaders. Use has climbed from 4% in 2024 to 11% now, but obesity is unlikely to become rare within a decade. Novo is much more compelling at current levels than Lilly. x.com 

Novo Nordisk's management showed too little action against near-term problems, leaving the case in real doubt for the first time. A 5-10-year recovery plan clashes with the semaglutide patent expiring within that window, already lost in Canada, India and Turkey, while Eli Lilly poses real threats. Pipeline work in blood/endocrine, liver and cardiovascular is exciting and diversifying would be a game changer, and NovoCare is a positive, but the clock is running and management is uninspiring. … Show more

Oral Wegovy removes one of the biggest barriers to GLP-1 adoption, yet investors are still sleeping on Novo Nordisk even though prescription data already show the launch going very well. Per @agingroy, Ozempic and Mounjaro generated $71 billion in 2025, more than OpenAI and Anthropic's combined $29 billion, and only about 2% of the 800 million eligible patients can currently access them. x.com 

Novo Nordisk stands to gain from Medicare access starting July 1, 2026, which could let millions of patients get Wegovy, including the new oral pill, for $50 a month. Novo leads on the convenient oral peptide pill while Lilly leads overall with tirzepatide, and Hims now partners with Novo and has stopped pushing most compounded versions. The weekly chart shows an inverse head-and-shoulders breakout. x.com 

Novo Nordisk carries too much legal drama to invest in, with lawsuits piling up. The latest, per @AIStockSavvy, is Viatris suing Novo over a patent dispute on generic Wegovy. x.com 

Novo Nordisk's investors will eventually focus on the potential of oral Wegovy and put past setbacks behind them, a certainty because the market is forward-looking. Reports say the orals are selling, and buyers have been accumulating the stock. x.com  x.com